Results 111 to 120 of about 882 (153)

Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2017
Vaborbactam (formerly RPX7009) is a new beta-lactamase inhibitor based on a cyclic boronic acid pharmacophore. The spectrum of beta-lactamase inhibition by vaborbactam and the impact of bacterial efflux and permeability on its activity were determined ...
Olga Lomovskaya, Ruslan Tsivkovski
exaly   +2 more sources

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
Olga Lomovskaya, Mojgan Sabet
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

An Update on Existing and Emerging Data for Meropenem-Vaborbactam

Clinical Therapeutics, 2020
The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders, Anthony M, Casapao, Veena, Venugopalan   +2 more
openaire   +2 more sources

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

International Journal of Antimicrobial Agents, 2023
Meropenem in combination with β-lactamase inhibitors (BLIs) and other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB).The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-TB) studies with ...
Sanjay Singh, Tawanda Gumbo, Jan-Willem Alffenaar, Gunavanthi D. Boorgula, Prem Shankar, Tania A. Thomas, Keertan Dheda, Lesibana Malinga, Prithvi Raj, Santosh Aryal, Shashikant Srivastava   +10 more
openaire   +3 more sources

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2017
We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Rodrigo Mendes, Michael Huband, Mariana Castanheira   +2 more
exaly   +2 more sources

An evaluation of meropenem/vaborbactam for the treatment of nosocomial pneumonia

Expert Opinion on Pharmacotherapy, 2020
Introduction: Nosocomial pneumonias are the second most common healthcare-associated infections (HCAIs), often associated with the presence of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter species, and Enterobacter species.
Lauren M. Groft, Kimberly C. Claeys, Emily L. Heil   +2 more
openaire   +2 more sources

Oxygenator impact on meropenem/vaborbactam in extracorporeal membrane oxygenation circuits

Perfusion, 2021
Introduction: To determine the oxygenator impact on alterations of meropenem (MEM)/vaborbactam (VBR) in a contemporary neonatal/pediatric (1/4-inch) and adolescent/adult (3/8-inch) extra corporeal membrane oxygenation (ECMO) circuit including the Quadrox-i ®
Jeffrey J Cies, Peter Nikolos, Wayne S Moore, Nadji Giliam, Tracy Low, Daniel Marino, Jillian Deacon, Adela Enache, Arun Chopra   +8 more
openaire   +2 more sources

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects

Antimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam is a fixed combination of the novel β-lactamase inhibitor vaborbactam and the carbapenem antibiotic meropenem, developed for the treatment of serious infections caused by drug-resistant Gram-negative bacteria.
Michael N Dudley
exaly   +2 more sources

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Rodrigo Mendes, Michael Huband, Mariana Castanheira   +2 more
exaly   +3 more sources

Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy, 2017
Vaborbactam (formerly RPX7009) is a new β-lactamase inhibitor based on a cyclic boronic acid pharmacophore with potent inhibitory activity against K lebsiella p neumoniae
Olga Lomovskaya, Dongxu Sun, Michael N Dudley   +2 more
exaly   +2 more sources